NVO News and Press, Novo Nordisk A/S From 06/11/24

2024-06-11 04:57:00 ET Shares of Structure Therapeutics (NASDAQ: GPCR) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clin...

2024-06-10 14:38:05 ET More on Eli Lilly, Novo Nordisk SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Eli Lilly's Growth And Challenges: A Cautious Buy SA Asks: Which weight-los...

2024-06-10 12:48:37 ET Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with ...

2024-06-10 12:06:11 ET Summary Hims & Hers stock has easily outperformed the market over the past year, surging almost 130%. Hims & Hers' personalized care platform is a critical growth driver poised to expand further. Hims & Hers is targeting the weight loss drugs...

2024-06-10 10:00:05 ET Jasper Hellweg from Argus Research issued a price target of $160.00 for NVO on 2024-06-10 08:41:00. The adjusted price target was set to $160.00. At the time of the announcement, NVO was trading at $142.88. The overall price target consensus is at ...

2024-06-09 08:47:48 ET Summary Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis. GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market. Madrigal's financ...

2024-06-09 07:30:00 ET Structure Therapeutics (NASDAQ: GPCR) might have something cooking that could one day unseat the likes of Novo Nordisk 's (NYSE: NVO) Ozempic, a drug for type 2 diabetes, as well as its drug Wegovy, which is the same medicine but branded and indicated ...

2024-06-08 09:00:00 ET Odds are that if you hear the word "Ozempic," you likely associate that with weight loss. It's hard not to given all the posts on social media about users losing weight thanks to the drug. But many people may be surprised that it's not actually approved as a weight lo...

2024-06-07 10:53:19 ET More on Kroger Kroger: Downside Risk Mounts As Merger Poses Lose-Lose Scenario Kroger Deserves More Love Kroger: Albertsons Merger Creates Highly Skewed Return Potential (Technical Analysis) Kroger drivers at Michigan fulfillment center...

2024-06-06 07:00:00 ET The medicine for type 2 diabetes called Ozempic is, without a doubt, Novo Nordisk 's (NYSE: NVO) knight in shining armor. Thanks to an impressive amount of demand and the company's dedicated efforts in exploring other conditions that the medicine could potenti...